Results 41 to 50 of about 21,696 (215)
Haematologica, 2019 Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity.
Alicia Arenas Cortés +11 more
doaj +1 more source
, 2022 Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis ...
Timothy Devos (13810354) +24 more
core +1 more source
Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
Case Reports in Oncological Medicine, 2020 Ruxolitinib has become a new therapeutic option for steroid refractory graft-versus-host disease (srGVHD), with a substantial remission rate. Its anti-inflammatory properties by blocking interleukin pathways have made it a novel therapeutic approach to ...
Philip T. Sobash +2 more
doaj +1 more source
Cancer Medicine, 2021 Preclinical observations that killing of chronic lymphocytic leukemia (CLL) cells was dexamethasone (DEX) were enhanced by concomitant inhibition of Bruton’s tyrosine kinase and janus kinases (JAKs) motivated a phase II trial to determine if clinical ...
David E. Spaner +5 more
doaj +1 more source
Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib [PDF]
, 2022 Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use
Lopes-Ramos, Teresa +21 more
core +1 more source
STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer. [PDF]
, 2022 PURPOSE: Increased activity of STAT3 is associated with progression of head and neck squamous cell carcinoma (HNSCC). Upstream activators of STAT3, such as JAKs, represent potential targets for therapy of solid tumors, including HNSCC.
Jose Rivera +27 more
core +1 more source
COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib
European Journal of Inflammation, 2021 We describe the case of a 78-year-old Italian woman with COVID-19 affected by Systemic Sclerosis with pulmonary fibrosis treated with Ruxolitinib (Ruxolitinib was provided free of charge by Novartis International AG).
Claudio Ucciferri +4 more
doaj +1 more source
Frontiers in Medicine, 2022 Data on the effect of ruxolitinib on antibody response to severe acute respiratory coronavirus 2 (SARS-CoV-2) vaccination in patients with myeloproliferative neoplasms (MPN) is lacking.
Daisuke Ikeda +11 more
doaj +1 more source
Pediatric Rheumatology Online Journal, 2021 Background This study aimed to analyze the effects of ruxolitinib on children with secondary hemophagocytic lymphohistiocytosis (HLH). Methods Eleven pediatric patients diagnosed with HLH and treated with ruxolitinib (ruxolitinib group: group R) between ...
Ying Chi +5 more
doaj +1 more source
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source